Arcus Biosciences to Participate in Three Upcoming Investor Conferences

News > Health News

Audio By Carbonatix

4:05 PM on Wednesday, August 20

The Associated Press

HAYWARD, Calif.--(BUSINESS WIRE)--Aug 20, 2025--

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in September:

Citi’s 2025 Biotech Back to School Conference
Date: Wednesday, September 3 rd, 2025
Location: Boston, MA
Format: Fireside chat & 1x1 meetings
Time: 11:15 a.m. ET

H.C. Wainwright 27 th Annual Global Investment Conference
Date: Tuesday, September 9 th, 2025
Location: New York, NY
Format: Fireside chat & 1x1 meetings
Time: 8:00 a.m. ET

Morgan Stanley 23 rd Annual Global Healthcare Conference
Date: Wednesday, September 10 th, 2025
Location: New York, NY
Format: Fireside chat & 1x1 meetings
Time: 8:30 a.m. ET

Live webcasts of the fireside chats will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. Replays will be available following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250820458174/en/

CONTACT: Investor Inquiries

Pia Eaves (Banerjee)

VP of Investor Relations & Strategy

(617) 459-2006

[email protected] Inquiries

Holli Kolkey

VP of Corporate Affairs

(650) 922-1269

[email protected] Bassiri

AD, Corporate Communications

(510) 406-8520